Relugolix

Introduction Overview

Generic Name

relugolix

Brand Name

Orgovyx

Dosage Form

oral tablet (120 mg)

Drug Class

gonadotropin-releasing hormone antagonists

Pharmacokinetics

Absorption:
Relugolix is administered orally and is well absorbed from the gastrointestinal tract. Following oral administration, Relugolix exhibits good bioavailability, allowing for adequate systemic exposure. The drug is rapidly absorbed, with peak plasma concentrations typically reached within a few hours post-dose. The initial loading dose strategy (300 mg once on Day 1 followed by 120 mg daily) is designed to rapidly achieve therapeutic plasma concentrations and testosterone suppression. Food has minimal effect on the absorption kinetics, allowing flexibility in dosing whether taken with or without food. The absorption profile supports once-daily oral administration, facilitating patient adherence.

Distribution:
Relugolix is distributed systemically after absorption, with evidence suggesting moderate plasma protein binding. Although exact volume of distribution data are limited, Relugolix's lipophilicity supports distribution into various tissues, including target tissues such as the pituitary and hypothalamus where GnRH receptors reside. Clinical data indicate that Relugolix achieves therapeutic concentrations capable of antagonizing pituitary GnRH receptors, effectively suppressing luteinizing hormone (LH) and follicle-stimulating hormone (FSH) secretion, and consequently reducing testosterone synthesis in the testes. The drug’s distribution characteristics ensure sufficient receptor engagement while maintaining systemic safety.

Metabolism:
Relugolix undergoes hepatic metabolism, primarily through cytochrome P450 enzymes, including CYP3A4, and possibly via other phase I and phase II enzymes. The metabolic pathways lead to several inactive metabolites excreted mainly in feces and urine. Drug metabolism can be influenced by concomitant administration of CYP3A4 inhibitors or inducers, which may alter Relugolix plasma levels and efficacy, necessitating careful monitoring or dose adjustment. The metabolic profile supports a predictable pharmacokinetic profile but requires consideration in polypharmacy contexts to avoid significant drug-drug interactions.

Elimination:
Elimination of Relugolix occurs primarily via biliary excretion into feces and to a lesser extent renal elimination. The elimination half-life supports once daily dosing, with steady-state concentrations reached within days of starting therapy. The drug clearance is moderately efficient, necessitating dose adjustments in cases of severe hepatic impairment, although specific guidelines and recommendations remain limited. Due to the elimination route, patients with severe liver or gastrointestinal diseases may require clinical monitoring to ensure optimal therapeutic levels and safety. Overall, the elimination pattern helps maintain consistent testosterone suppression with once-daily oral Relugolix administration.

Dosage Forms

Available Dosage Forms:
Relugolix is provided as an oral film-coated tablet with a strength of 120 mg per tablet. The tablets are light red, almond-shaped, and debossed with “R” on one side and “120” on the other. The formulation includes inactive ingredients such as mannitol, sodium starch glycolate, hydroxypropyl cellulose, magnesium stearate, hypromellose, titanium dioxide, ferric oxide red, and carnauba wax.

Dosages for Adults and Adolescents:
For adult males with advanced prostate cancer, the recommended dosing regimen begins with a loading dose of 300 mg (administered as three 120 mg tablets simultaneously) on the first day of treatment to rapidly suppress testosterone levels. Following this, a maintenance dose of 120 mg once daily is prescribed to maintain castrate levels of testosterone. The drug should be taken at the same time each day, with or without food. Swallow tablets whole without crushing, chewing, or breaking.

Specific Patient Populations:
Relugolix is intended exclusively for use in adult men with advanced prostate cancer. It is not approved for pediatric use or for women as monotherapy, although it may be used in combination with other therapies for certain indications. Patients with hepatic impairment should be monitored closely due to hepatic metabolism, and dosing adjustments may be necessary although specific recommendations are not well-established. No specific dosage recommendations exist for renal impairment, but caution is advised.

Clinical Guidelines:
Treatment duration is determined by clinical response and physician discretion, with therapy generally continued even in castration-resistant metastatic or nonmetastatic prostate cancer following initial suppression. Frequent monitoring of testosterone levels and cardiovascular status, including ECG monitoring, is advised. Because of potential drug interactions and impact on heart rhythm (QT prolongation risk), strict adherence to dosing schedules and avoidance of concomitant interacting drugs is critical.

Mechanism Of Action

Relugolix is a potent, selective oral gonadotropin-releasing hormone (GnRH) receptor antagonist that competitively inhibits the binding of endogenous GnRH at the pituitary GnRH receptor sites. By blocking this receptor, Relugolix prevents the normal pulsatile GnRH stimulation required for the synthesis and release of the gonadotropins luteinizing hormone (LH) and follicle-stimulating hormone (FSH).

The primary biochemical effect results in rapid suppression of LH secretion, which in turn diminishes testicular testosterone production drastically. Unlike GnRH agonists, which initially cause a surge or flare of LH and testosterone before downregulation, Relugolix immediately inhibits GnRH receptor activity without the initial hormone surge. This leads to more rapid testosterone suppression, typically reaching castrate levels within days of treatment initiation.

At a molecular level, the blockade of GnRH receptors downregulates downstream intracellular signaling pathways involving G-protein coupled receptors that influence cyclic AMP synthesis and calcium mobilization, thus impeding gonadotropin release. The consequent low testosterone environment inhibits the growth and proliferation of testosterone-dependent prostate cancer cells, leading to reduced tumor progression.

Clinically, Relugolix’s oral administration and rapid onset provide advantages over injectable GnRH agonists, minimizing flare-related complications such as bone pain and urinary obstruction. Research studies, including pivotal phase 3 trials, have demonstrated Relugolix’s sustained ability to maintain castrate testosterone levels with a favorable safety profile, supporting its use in androgen deprivation therapy for advanced prostate cancer. Comparative analyses indicate that Relugolix provides equivalent or superior testosterone suppression with fewer cardiovascular adverse events than traditional agents such as leuprolide.

Pharmacological Actions

Selective antagonism of gonadotropin-releasing hormone (GnRH) receptors in the pituitary gland.
Rapid suppression of luteinizing hormone (LH) secretion, leading to decreased testosterone synthesis in the testes.
Inhibition of follicle-stimulating hormone (FSH) release, contributing to reproductive hormone regulation.
Reduction of circulating testosterone to castrate levels, limiting androgen-dependent tumor growth.
Prevention of initial testosterone surge commonly seen with GnRH agonists, minimizing disease flare effects.
Modulation of hormonal signaling pathways involved in reproductive endocrinology.
Oral bioavailability allowing convenient once-daily dosing.
Minimal partial agonist activity, enabling direct receptor blockade without receptor activation.
Dose-dependent and sustained suppression of androgen production upon continuous administration.
Potential neuroendocrine effects due to feedback interruption on hypothalamic-pituitary-gonadal axis.

Therapeutic Or Clinical Uses

Treatment of advanced prostate cancer in adult men.
Used in androgen deprivation therapy to reduce testosterone levels.
Management of patients with nonmetastatic or metastatic castration-resistant prostate cancer following initial hormone therapy.
Alternative to injectable GnRH agonists for chemical castration.
Adjunct therapy to slow progression of testosterone-dependent malignancies.
Option for patients experiencing adverse effects or contraindications with GnRH agonist therapy.
Facilitation of rapid testosterone suppression to minimize tumor flare symptoms.
Part of combination regimens in clinical trials for prostate cancer treatment.
Potential off-label research interest in conditions involving sex hormone regulation.

Side Or Adverse Effects

Flushing characterized by sudden warmth, redness, or tingling sensation.
Fatigue and general tiredness reported during therapy.
Elevated blood glucose levels and risk of hyperglycemia.
Increases in cholesterol and triglyceride levels (dyslipidemia).
Anemia or reduced red blood cell counts observed on laboratory testing.
Depressed mood or signs of mood disturbance.
Weight gain potentially related to hormonal changes.
Impotence and sexual dysfunction due to androgen deprivation.
Gynecomastia or abnormal breast tissue growth in males.
Gastrointestinal disturbances including diarrhea and constipation.
Muscle and joint pain, possibly related to hormonal effects on musculoskeletal system.
Abnormal liver and blood laboratory test results indicating hepatic or hematologic effects.
Rare but serious allergic reactions including hives, facial swelling, and breathing difficulties.
Cardiac symptoms such as palpitations, chest pain, or arrhythmia may occur.
Increased risk of cardiovascular events, notably in patients with pre-existing heart conditions.

Precautions

Use with caution in patients with known cardiovascular disease due to risk of QT prolongation and arrhythmia.
Monitor for electrolyte imbalances which can exacerbate cardiac risks.
Closely observe patients with diabetes or dyslipidemia as metabolic parameters may worsen.
Patients should inform healthcare providers of any history of long QT syndrome or familial arrhythmias.
Relugolix can impair male fertility; effective contraception is recommended during treatment and for 2 weeks after discontinuation.
Avoid use in women as monotherapy due to lack of efficacy and potential fetal harm.
Pregnant partners of male patients should be advised of potential risks to the fetus; contraception strongly advised.
Periodic cardiovascular evaluation including ECG monitoring is recommended during therapy.
Monitor blood counts regularly to assess for anemia and other hematologic abnormalities.
Watch for depressive symptoms or mood changes and provide appropriate support.
Adherence to dosing regimen is critical to maintain therapeutic testosterone suppression.
Do not abruptly discontinue therapy without physician guidance to avoid hormone rebound effects.
Inform patients about possible gastrointestinal side effects and advise supportive care if needed.
Store medication properly to preserve efficacy and avoid degradation.
Healthcare providers should educate patients on signs of severe adverse events requiring immediate medical attention.

Warnings

Relugolix may cause a decrease in male fertility; use effective contraception to prevent pregnancy.
This medication is intended solely for use in men; not approved as monotherapy in women due to fetal harm risk.
Use is contraindicated in patients with known hypersensitivity to relugolix or its components.
Patients with personal or family history of long QT syndrome should avoid relugolix due to risk of fatal arrhythmias.
May cause serious cardiac adverse effects including QT prolongation, irregular heartbeat, chest pain, and dizziness.
Concomitant use with other drugs that prolong QT interval or affect cardiac conduction requires extreme caution.
Risk of severe allergic reactions mandates immediate discontinuation and emergency care if symptoms occur.
Potential for interaction with multiple drug classes that may increase toxicity or reduce effectiveness.
Use caution in patients with impaired liver function due to metabolism via hepatic pathways.
Abrupt discontinuation can lead to testosterone rebound potentially worsening disease symptoms.
Increased risk of cardiovascular events especially in patients with underlying heart failure or comorbidities.
Avoid concurrent administration with certain antibiotics, antifungals, antimalarials, and psychiatric medications within six hours of Relugolix dosing.
Patients should report any unusual bleeding, urinary symptoms, or neuromuscular symptoms promptly.
Not to be flushed; proper disposal methods are essential to prevent environmental contamination.
Emergency treatment should be sought immediately for life-threatening adverse effects.

Contraindication

Known allergy or hypersensitivity to relugolix or any of the tablet's inactive ingredients.
Patients with diagnosed long QT syndrome or family history of this condition.
Individuals with active serious cardiac arrhythmias or unstable cardiovascular disorders.
Women who are pregnant or may become pregnant, due to potential fetal toxicity.
Patients with severe hepatic impairment where drug metabolism may be compromised.
Concurrent use of medications that are contraindicated due to interaction risk and QT prolongation.
Patients with known hypersensitivity reactions to other GnRH receptor antagonists if cross-reactive.
Use in pediatric patients has not been established and is contraindicated.
Known hypersensitivity to components such as mannitol, hypromellose, or titanium dioxide.
History of severe allergic reactions to hormonal therapies that may indicate cross-reactivity.

Drug Interactions

Concomitant use with drugs known to prolong QT interval (e.g., certain antiarrhythmics, macrolide antibiotics) increases risk of serious cardiac arrhythmias.
Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin) may increase plasma levels of relugolix, enhancing toxicity risk.
CYP3A4 inducers (e.g., rifampin, carbamazepine) can reduce relugolix effectiveness by increasing its metabolism.
Drugs such as antihistamines, antidepressants, antipsychotics, and some antifungals may interact to prolong QT interval.
Concurrent administration with HIV protease inhibitors or antimalarial drugs requires careful scheduling to avoid interactions.
Medications for asthma, high blood pressure, or mental illness may interact adversely with relugolix.
Herbal supplements and over-the-counter vitamins should be disclosed to healthcare providers as unrecognized interactions may occur.
Certain medications should not be taken within six hours after relugolix dosing; relugolix must be taken first daily.
Potential increases in blood glucose and lipid parameters require monitoring when combined with antidiabetic or lipid-lowering agents.
Co-administration with drugs affecting electrolyte balance (e.g., diuretics) may increase risk of cardiac adverse events.
Warfarin and other anticoagulants should be used with caution, considering potential bleeding risks.
Interactions with corticosteroids or other hormonal therapies may alter therapeutic effect or side-effect profile.
Close monitoring when combining with immunosuppressive or chemotherapy agents to avoid additive toxicities.
Relugolix may affect the pharmacokinetics of concomitant drugs metabolized by hepatic enzymes; dose adjustments may be necessary.
Patients should inform all healthcare providers of relugolix therapy to manage drug interactions effectively.

Preparations Of The Drug

Relugolix oral tablet 120 mg, film-coated, light red, almond shaped, debossed with 'R' and '120'.
Formulation includes inactive ingredients: mannitol, sodium starch glycolate, hydroxypropyl cellulose, magnesium stearate, hypromellose, titanium dioxide, ferric oxide red, and carnauba wax.
Supplied in moisture-protected containers to maintain tablet integrity and potency.
Packaging includes moisture-absorbing packets or canisters to prevent degradation.
Manufactured under strict quality control by Myovant Sciences, Inc., Brisbane, CA.
Intended for oral administration with instructions to swallow whole without crushing or chewing.
Storage recommended at room temperature, away from heat and moisture.
Disposal instructions specify not flushing tablets; unused medication should be returned through drug take-back programs, or disposed by mixing with cat litter or coffee grounds and sealed in a plastic bag.
Available only by prescription with detailed patient information leaflets included.
Formulation optimized for once-daily dosing to enhance patient compliance.